KLINX helps family offices, investment holdings and strategic investors evaluate where to deploy capital, under what conditions, with which risks, and with what expected return profile.
2-minute confidential intake · Response within 24 hours
We do not sell generic business plans. We build decision infrastructure: research, market intelligence, feasibility analysis, financial logic and investment-ready recommendations.
Answer one high-value investment question quickly, with a clear GO / CONDITIONAL GO / NO-GO recommendation.
Market sizing, competitive intelligence, unit economics, scenario modelling, entry strategy and investment memorandum.
Deep commercial intelligence before entering, acquiring or financing an African business, platform or project.
Outsourced intelligence desk for opportunity screening, sector scans, country intelligence and investment committee support.
Ongoing high-trust intelligence function for family offices and investment groups with repeated Africa exposure.
Country comparison, regulatory mapping, partner ecosystem, operating constraints, commercial validation and risk architecture.
“The opportunity is not ‘Africa’. The opportunity is the narrow intersection of market, sector, operator, structure and risk allocation.”
Every mandate begins with the decision to be made—not the document to be produced.
Clarify capital, geography, sector, horizon, return profile and decision deadline.
Primary and secondary research, market sizing, stakeholder and ecosystem intelligence.
Scenario analysis, risks, regulatory, FX, operating model and financial assumptions.
Decision memo, investment case, board/investment committee briefing and next-step roadmap.
Request a confidential review. KLINX accepts a limited number of high-value engagements where rigorous intelligence can materially improve capital allocation.
Submit Your Investment Brief — Confidential2-minute confidential intake · Response within 24 hours
Submit your investment brief securely for confidential review by KLINX.
By submitting, you consent to KLINX confidentially reviewing this information.